This page uses content from Wikipedia and is licensed under CC BY-SA.

Indacaterol/glycopyrronium bromide

Indacaterol/glycopyrronium bromide
Indacaterol and glycopyrronium bromide.svg
Combination of
IndacaterolUltra-long-acting beta-adrenoceptor agonist
Glycopyrronium bromideMuscarinic anticholinergic
Clinical data
Trade namesUltibro Breezhaler, Utibron Neohaler
Routes of
Inhalation only
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • In general: ℞ (Prescription only)
CAS Number
PubChem CID
CompTox Dashboard (EPA)

Indacaterol/glycopyrronium bromide is a combination drug for inhalation consisting of the following two active ingredients:

Indacaterol maleate/glycopyrronium bromide is used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).[2]

The drug is marketed by Novartis under the trade names Ultibro Breezhaler and Utibron Neohaler in Europe and the United States, respectively.[2][3]


  1. ^ Cazzola M, Matera MG, Lötvall J (July 2005). "Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease". Expert Opin Investig Drugs. 14 (7): 775–83. doi:10.1517/13543784.14.7.775. PMID 16022567.
  2. ^ a b "Ultibro Breezhaler". DataPharm. 2015-02-03. Retrieved 2015-02-09.
  3. ^ "Approval History: NDA 207930". [email protected]. US FDA. Retrieved 14 May 2016.